Development of novel tracers for sentinel node identification in cervical cancer
Cancer Science · 2023
DOI: 10.1111/cas.15927 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2023. Verfasst von Keisuke Kodama und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Sentinel Lymph Node, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Grant-in-Aid for Scientific Research, Kyushu University School of Medicine Obstetrics and Gynecology Research Fund, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Indocyanine green (ICG) with near‐infrared (NIR) fluorescence imaging is used for lymphatic mapping. However, binding of ICG to blood proteins like serum albumin can shorten its retention time in sentinel lymph nodes (SLNs). Here, we investigated the efficacy and safety of a new fluorescence tracer comprising phytate and liposome (LP)‐encapsulated ICG. Coadministration of phytate with LP containing phosphatidic acid promotes chelation mediated by Ca 2+ in bodily fluids to enhance SLN retention. Uniformly sized LPs (100 nm) encapsulating ICG under conditions that minimized fluorescence self‐quenching during storage were produced. We analyzed the behavior of the new tracer (ICG‐phytate‐LP) and control tracers (ICG and ICG‐LP) in the lymphatic flow of mice in terms of lymph node retention time. We also tested lymphatic flow and safety in pigs that have a more human‐like lymphatic system. LPs encapsulating stabilized ICG were successfully prepared. Mixing LP with phytate in the presence of Ca 2+ increased both the particle size and negative surface charge. In mice, ICG‐phytate‐LP had the best lymph node retention, with a fluorescence intensity ratio that increased over 6 h and then decreased slowly over the next 24 h. In pigs, administration of ICG and ICG‐phytate‐LP resulted in no death or weight loss. There were no obvious differences between blood test results for the ICG and ICG‐phytate‐LP groups, and the overall safety was good. ICG‐phytate‐LP may be a useful new tracer for gynecological cancers that require time for lymph node identification due to a retroperitoneal approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Chemistry and Biochemistry, Graduate School of Systems Life Sciences, Graduate School of Engineering, Kyushu University, Fukuoka, Japan.
- Department of Biomedical Engineering, Chung Yuan Christian University, Taoyuan City, Taiwan.
ORCID-Profile: Keisuke Kodama
Förderung
- Grant-in-Aid for Scientific Research, Kyushu University School of Medicine Obstetrics and Gynecology Research Fund
- Japan Society for the Promotion of Science
Zitieren
APA
Kodama, K., Tateishi, C., Oda, T., Cui, L., Kuramoto, K., Yahata, H., Okugawa, K., Maenohara, S., Yagi, H., Yasunaga, M., Onoyama, I., Asanoma, K., Mori, T., Katayama, Y., & Kato, K. (2023). Development of novel tracers for sentinel node identification in cervical cancer. Cancer Science. https://doi.org/10.1111/cas.15927
Vancouver
Kodama K, Tateishi C, Oda T, Cui L, Kuramoto K, Yahata H, et al. Development of novel tracers for sentinel node identification in cervical cancer. Cancer Science. 2023. doi:10.1111/cas.15927
BibTeX
@article{Kodama2023,
author = {Kodama, Keisuke and Tateishi, Chuya and Oda, Tsuyoshi and Cui, Lin and Kuramoto, Kazutaka and Yahata, Hideaki and Okugawa, Kaoru and Maenohara, Shoji and Yagi, Hiroshi and Yasunaga, Masafumi and Onoyama, Ichiro and Asanoma, Kazuo and Mori, Takeshi and Katayama, Yoshiki and Kato, Kiyoko},
title = {Development of novel tracers for sentinel node identification in cervical cancer},
journal = {Cancer Science},
year = {2023},
doi = {10.1111/cas.15927}
}
EUVIMED